Wolfgang Hiddemann

Wolfgang Hiddemann publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Wolfgang Hiddemann sits on this spectrum.

Wolfgang Hiddemann D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Wolfgang Hiddemann sits on this spectrum.

Research.com Recognitions

• 2023 - Research.com Medicine in Germany Leader Award

Overview

Best Publications

• Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

  Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner

  3855
  Citations

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma

  James O. Armitage

  3470
  Citations

• Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

  Wolfgang Hiddemann;Michael Kneba;Martin Dreyling;Norbert Schmitz

  1928
  Citations

• Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

  Susanne Schnittger;Claudia Schoch;Martin Dugas;Wolfgang Kern

  1438
  Citations

• Dominant-negative mutations of CEBPA , encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia

  Thomas Pabst;Beatrice U. Mueller;Pu Zhang;Hanna S. Radomska

  1131
  Citations

• A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

  Eva Hoster;Martin Dreyling;Wolfram Klapper;Christian Gisselbrecht

  1060
  Citations

• Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.

  Martin Schrappe;Alfred Reiter;Wolf-Dieter Ludwig;Jochen Harbott

  930
  Citations

• Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

  Susanne Schnittger;Claudia Schoch;Wolfgang Kern;Cristina Mecucci

  908
  Citations

• Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86

  A Reiter;M Schrappe;WD Ludwig;W Hiddemann

  895
  Citations

• The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

  Roswitha Forstpointner;Martin Dreyling;Roland Repp;Sandra Hermann

  846
  Citations

• Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

  Georg Lenz;Martin Dreyling;Eva Hoster;Bernhard Wörmann

  821
  Citations

• A 17-gene stemness score for rapid determination of risk in acute leukaemia

  Stanley W. K. Ng;Amanda Mitchell;James A. Kennedy;James A. Kennedy;James A. Kennedy;Weihsu C. Chen

  788
  Citations

• Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

  Martin Dreyling;Georg Lenz;Eva Hoster;Achiel Van Hoof

  753
  Citations

• Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

  Rolf D Issels;Lars H Lindner;Jaap Verweij;Peter Wust

  722
  Citations

• Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

  Robert Marcus;Andrew Davies;Kiyoshi Ando;Wolfram Klapper

  696
  Citations

• Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

  Alessandro Pastore;Vindi Jurinovic;Robert Kridel;Eva Hoster

  683
  Citations

• Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

  Roswitha Forstpointner;Michael Unterhalt;Martin Dreyling;Hans-Peter Böck

  650
  Citations

• Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia

  Stephen Johnson;Alister G. Smith;Helmut Löffler

  640
  Citations

• Treatment of Older Patients with Mantle-Cell Lymphoma

  H. C. Kluin-Nelemans;Eva Hoster;Olivier Hermine;J. Walewski

  619
  Citations

• Convention on nomenclature for DNA cytometry

  Wolfgang Hiddemann;Johannes Schumann;Michael Andreef;Barthel Barlogie

  251
  Citations